Eupraxia is a clinical-stage biotech company developing locally delivered, extended-release alternatives to currently approved drugs. Eupraxia's product candidates have the potential to address therapeutic areas with high unmet medical needs and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects.